Presenting a Patient with Severe Hemophilia A and Acute Hemarthrosis on Rounds
When presenting a 32-year-old male with severe hemophilia A (factor VIII <1%) and acute left knee hemarthrosis, structure your presentation around disease severity classification, current bleeding episode characteristics, inhibitor status, prophylaxis regimen, and joint damage assessment—these are the critical determinants of morbidity and mortality that will guide immediate and long-term management.
Essential Opening Statement
Lead with:
- Age, hemophilia type and severity (factor VIII activity level <1% defines severe disease) 1
- Inhibitor status (present in 20-35% of severe hemophilia A patients) 1
- Current prophylaxis regimen (or lack thereof)
- Presenting complaint: acute left knee hemarthrosis with specific timing, trauma history, and functional impact
Core Clinical Data Points to Present
Disease Characterization
- Factor VIII activity level: Must state the exact percentage (<1 IU/dL = severe) 1
- Inhibitor history: Critical because this completely changes management
- If inhibitor-positive: state Bethesda units (high-titer >5 BU vs low-titer)
- Inhibitors occur in 20-35% of severe hemophilia A patients 1
- Genetic mutation if known (F8 genotype influences inhibitor risk) 1
Current Bleeding Episode
- Joint involved (knee is most common site) 2, 3
- Time from symptom onset to presentation (delays >3 hours worsen outcomes) 4
- Presence of risk factors: pain, tenderness, >50% loss of movement 4
- Trauma history (spontaneous vs traumatic—severe hemophilia causes spontaneous bleeds) 1
- Number of bleeding episodes this year (frequency indicates adequacy of prophylaxis)
Treatment History
- Current prophylaxis regimen:
- Type of factor concentrate (recombinant vs plasma-derived, standard vs extended half-life)
- Dosing frequency and adherence
- If on emicizumab (non-replacement therapy for prophylaxis) 5
- Factor replacement given for current bleed: dose, timing, number of doses
- Annual bleeding rate (ABR)—key metric for treatment adequacy
Joint Assessment
- Target joint status: Is this a target joint (≥3 bleeds in same joint within 6 months)?
- Chronic synovitis present or not (prelude to hemophilic arthropathy) 2
- Range of motion: specific degrees of flexion/extension
- Deformities: varus/valgus angulation, flexion contractures 6
- Imaging findings if available (X-ray, ultrasound, or MRI showing cartilage damage, joint space narrowing)
Complications Screening
- Hemophilic arthropathy in other joints (ankle, elbow are next most common) 2, 3
- Transfusion-transmitted infections: HBV, HCV, HIV status (historical concern with older concentrates) 7
- Venous access: presence of port or central line (relevant for prophylaxis feasibility)
Coordination with Hematology/Oncology Consultant
Information to Have Ready
- Exact factor VIII level and when last checked
- Inhibitor titer (Bethesda assay) and date
- Complete treatment history:
- Cumulative exposure days to factor VIII
- Previous inhibitor episodes
- Current prophylaxis details
- Bleeding phenotype severity relative to factor level (some moderate hemophilia patients bleed like severe) 1
Key Questions for Heme/Onc
- Immediate: Appropriate factor dosing for this hemarthrosis (typically 40-50 IU/kg for joint bleeds)
- If inhibitor present: Need for bypassing agents (recombinant FVIIa or activated prothrombin complex concentrate) 1, 5
- Prophylaxis optimization: Is current regimen adequate given breakthrough bleeding?
- Chronic synovitis management: Candidacy for radiosynovectomy if recurrent bleeds in same joint 2
Critical Pitfalls to Highlight
Inhibitor Development
- Most important complication affecting 20-35% of severe hemophilia A patients 1
- Renders standard factor replacement ineffective
- Requires bypassing agents or emicizumab 5
- If patient has inhibitor, never assume standard factor VIII will work
Delayed Treatment
- Hemarthroses presenting >3 hours after onset have worse outcomes 4
- Early aggressive treatment prevents chronic arthropathy 3
Undertreated Chronic Synovitis
- Recurrent bleeding in same joint → chronic synovitis → irreversible arthropathy 2, 3
- Prophylaxis prevents this cascade (strong recommendation for severe hemophilia A) 1
Emicizumab Considerations
- If patient is on emicizumab for prophylaxis, avoid activated prothrombin complex concentrate due to thrombotic microangiopathy risk 5
- Can use recombinant FVIIa if bypassing agent needed 5
Presentation Framework for Rounds
Opening: "This is a 32-year-old male with severe hemophilia A, factor VIII activity <1%, [inhibitor-positive/negative], on [specific prophylaxis regimen], presenting with acute left knee hemarthrosis."
HPI: Detail onset, trauma, prior bleeds in this joint, treatment given, response.
Past Medical History:
- Hemophilia diagnosis age
- Inhibitor history
- Target joints
- Chronic arthropathy
- Transfusion-transmitted infection status
Current Regimen: Exact prophylaxis details, adherence, ABR on current regimen
Physical Exam: Joint-specific findings (swelling, warmth, ROM in degrees, deformity)
Assessment: "Acute hemarthrosis in setting of severe hemophilia A [with/without inhibitor]. [This is/is not] a target joint. Current prophylaxis [is/is not] adequate given [X] bleeding episodes this year."
Plan: